Patients with advanced non–small cell lung cancer (NSCLC) harboring KRAS G12C mutations benefitted from therapy with sotorasib (formerly AMG 510), an inhibitor of KRAS G12C, which induced a 6.8-month median progression-free survival. These results from the CodeBreaK 100 trial (NCT03600883) were presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore.1,2
The confirmed objective response rate (ORR) and a disease control rate were 37.1% and 80.6%, respectively, at a median follow-up of 12.2 months. The median duration of response was 10 months.
These data show that sotorasib is the first KRAS G12C inhibitor to show PFS in a phase 2 study, stated Amgen, the manufacturer of the agent.
“These results are encouraging and clinically meaningful for patients with advanced NSCLC harboring the KRAS G12C mutation,” said lead…
